(0.30%) 5 115.10 points
(0.24%) 38 332 points
(0.32%) 15 979 points
(-0.76%) $83.21
(2.55%) $1.972
(-0.05%) $2 346.10
(-0.05%) $27.52
(3.03%) $950.05
(-0.10%) $0.934
(-0.13%) $11.01
(-0.32%) $0.798
(1.77%) $93.50
@ $6.23
发出时间: 15 Feb 2024 @ 04:20
回报率: -53.13%
上一信号: Feb 14 - 23:48
上一信号:
回报率: -7.02 %
Live Chart Being Loaded With Signals
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine...
Stats | |
---|---|
今日成交量 | 16 343.00 |
平均成交量 | 283 248 |
市值 | 16.10M |
EPS | $0 ( 2024-02-15 ) |
下一个收益日期 | ( $-2.20 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.150 |
ATR14 | $0.0200 (0.68%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-12 | Cr Group L.p. | Buy | 1 647 315 | Common Stock |
2024-04-12 | Cr Group L.p. | Buy | 390 142 | Common Stock |
2024-04-12 | Cr Group L.p. | Buy | 682 036 | Common Stock |
2024-04-12 | Cr Group L.p. | Buy | 424 716 | Common Stock |
2024-04-12 | Cr Group L.p. | Buy | 136 409 | Common Stock |
INSIDER POWER |
---|
3.77 |
Last 99 transactions |
Buy: 52 592 861 | Sell: 43 240 632 |
音量 相关性
T2 Biosystems Inc 相关性 - 货币/商品
T2 Biosystems Inc 财务报表
Annual | 2023 |
营收: | $7.19M |
毛利润: | $-8.83M (-122.74 %) |
EPS: | $-19.19 |
FY | 2023 |
营收: | $7.19M |
毛利润: | $-8.83M (-122.74 %) |
EPS: | $-19.19 |
FY | 2022 |
营收: | $22.31M |
毛利润: | $1.17M (5.23 %) |
EPS: | $-1 242.48 |
FY | 2021 |
营收: | $28.06M |
毛利润: | $7.36M (26.21 %) |
EPS: | $-20.29 |
Financial Reports:
No articles found.
T2 Biosystems Inc
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。